WO2007017219A3 - Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility - Google Patents

Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility Download PDF

Info

Publication number
WO2007017219A3
WO2007017219A3 PCT/EP2006/007783 EP2006007783W WO2007017219A3 WO 2007017219 A3 WO2007017219 A3 WO 2007017219A3 EP 2006007783 W EP2006007783 W EP 2006007783W WO 2007017219 A3 WO2007017219 A3 WO 2007017219A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained
strong
active ingredient
ingredient release
pharmaceutical form
Prior art date
Application number
PCT/EP2006/007783
Other languages
French (fr)
Other versions
WO2007017219A2 (en
Inventor
Claudia Guthmann
Heiko Kranz
Ralph Lipp
Torsten Wagner
Original Assignee
Schering Ag
Claudia Guthmann
Heiko Kranz
Ralph Lipp
Torsten Wagner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Claudia Guthmann, Heiko Kranz, Ralph Lipp, Torsten Wagner filed Critical Schering Ag
Priority to EP06776644A priority Critical patent/EP1926482A2/en
Priority to JP2008524453A priority patent/JP2009503011A/en
Priority to CA002617280A priority patent/CA2617280A1/en
Publication of WO2007017219A2 publication Critical patent/WO2007017219A2/en
Publication of WO2007017219A3 publication Critical patent/WO2007017219A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Solid pharmaceutical formulation for a sustained pH-independent active ingredient release comprising at least one layer of one or more water-insoluble polymers, at least one layer of one or more pH-dependently water-soluble polymers and an active ingredient-containing core, having strong pH-dependent water solubility and comprises at least one osmagent.
PCT/EP2006/007783 2005-08-05 2006-08-02 Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility WO2007017219A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06776644A EP1926482A2 (en) 2005-08-05 2006-08-02 Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility
JP2008524453A JP2009503011A (en) 2005-08-05 2006-08-02 Pharmaceutical forms with sustained pH-independent active ingredient release for active ingredients with strong pH-dependent solubility
CA002617280A CA2617280A1 (en) 2005-08-05 2006-08-02 Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05090228A EP1749519A1 (en) 2005-08-05 2005-08-05 Dosage form with pH-independent sustained release for active substances with pH-dependent solubility
EP05090228.7 2005-08-05
US70642805P 2005-08-09 2005-08-09
US60/706,428 2005-08-09

Publications (2)

Publication Number Publication Date
WO2007017219A2 WO2007017219A2 (en) 2007-02-15
WO2007017219A3 true WO2007017219A3 (en) 2007-06-28

Family

ID=35448205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007783 WO2007017219A2 (en) 2005-08-05 2006-08-02 Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility

Country Status (11)

Country Link
EP (2) EP1749519A1 (en)
JP (1) JP2009503011A (en)
CN (1) CN101257895A (en)
AR (1) AR055110A1 (en)
CA (1) CA2617280A1 (en)
DO (1) DOP2006000184A (en)
GT (1) GT200600353A (en)
PE (1) PE20070464A1 (en)
TW (1) TW200738285A (en)
UY (1) UY29728A1 (en)
WO (1) WO2007017219A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007346A1 (en) * 2006-05-08 2008-12-31 McNeil-PPC, Inc. Osmotic dosage form
JP5228359B2 (en) * 2007-04-12 2013-07-03 ニプロ株式会社 Active ingredient particles, process for producing the same and orally disintegrating tablets
EP2598123A1 (en) * 2010-07-27 2013-06-05 Norgine BV Compositions
CN103093211B (en) * 2013-01-27 2015-09-30 西安电子科技大学 Based on the human body motion tracking method of deep nuclear information image feature

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
EP0277925A1 (en) * 1987-01-15 1988-08-10 Lejus Medical Aktiebolag Diuretic composition
WO1995030422A1 (en) * 1994-05-06 1995-11-16 Pfizer Inc. Controlled-release dosage forms of azithromycin
WO2003035037A1 (en) * 2001-10-18 2003-05-01 Schering Aktiengesellschaft Solid pharmaceutical formulation for a piperazine urea derivative
US20050106252A1 (en) * 2002-03-14 2005-05-19 Karl Kolter Combination of polyvinyl acetate with water-insoluble, acid-insoluble, or alkali-insoluble polymers used for the production of film coatings with highly controlled release and high stability

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
WO2001076557A1 (en) * 2000-04-10 2001-10-18 Sumitomo Pharmaceuticals Co., Ltd. Sustained release preparations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
EP0277925A1 (en) * 1987-01-15 1988-08-10 Lejus Medical Aktiebolag Diuretic composition
WO1995030422A1 (en) * 1994-05-06 1995-11-16 Pfizer Inc. Controlled-release dosage forms of azithromycin
WO2003035037A1 (en) * 2001-10-18 2003-05-01 Schering Aktiengesellschaft Solid pharmaceutical formulation for a piperazine urea derivative
US20050106252A1 (en) * 2002-03-14 2005-05-19 Karl Kolter Combination of polyvinyl acetate with water-insoluble, acid-insoluble, or alkali-insoluble polymers used for the production of film coatings with highly controlled release and high stability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1926482A2 *

Also Published As

Publication number Publication date
WO2007017219A2 (en) 2007-02-15
EP1926482A2 (en) 2008-06-04
PE20070464A1 (en) 2007-06-07
CA2617280A1 (en) 2007-02-15
DOP2006000184A (en) 2007-05-31
TW200738285A (en) 2007-10-16
CN101257895A (en) 2008-09-03
UY29728A1 (en) 2007-02-28
JP2009503011A (en) 2009-01-29
GT200600353A (en) 2007-03-14
EP1749519A1 (en) 2007-02-07
AR055110A1 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
WO2007036952A3 (en) Novel sustained release dosage form
WO2009117130A3 (en) Extended release forumulation containing a wax
WO2008109462A3 (en) Sustained release pellets comprising wax-like material
EP1364643A4 (en) Composition improved in solubility or oral absorbability
DK1792927T3 (en) New block copolymer, micelle preparation and anticancer agent containing the same as active ingredient
WO2006009987A3 (en) Dissolvable film composition
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EP2322146A3 (en) Microcapsule formulations comprising two pharmaceutically active ingredients
NO20082988L (en) Sustained release formulation including octreotide and two or more polylactide co-glycolide polymers
WO2006039499A3 (en) Method for improving the biovailability of orally delivered therapeutics
WO2005065661A3 (en) Immediate, controlled and sustained release formulations of galanthamine
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2002058672A3 (en) Microparticles of biodegradable polymer encapsulating a biologically active substance
WO2006123364A3 (en) Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative
WO2005020962A8 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
WO2008060934A3 (en) Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
WO2007146293A3 (en) Improved composition and method for taste masking
WO2007017219A3 (en) Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
WO2009130225A3 (en) Self-microemulsifying systems incorporated into liquid core microcapsules
WO2006026174A3 (en) Matrix composition for stable microemulsions
MX2007013327A (en) Extended release formulations.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2617280

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008524453

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200680028842.1

Country of ref document: CN

Ref document number: 1020087002921

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 995/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006776644

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006776644

Country of ref document: EP